Institute for Prevention and Occupational Medicine, German Social Accident Insurance, Ruhr-University Bochum (IPA), Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany.
BMC Cancer. 2010 May 28;10:242. doi: 10.1186/1471-2407-10-242.
Calretinin is one of the well-established immunohistochemical markers in the diagnostics of malignant mesothelioma (MM). Its utility as a diagnostic tool in human blood, however, is scarcely investigated. The aim of this study was to develop an enzyme-linked immunosorbent assay (ELISA) for human calretinin in blood and to assess its usefulness as a potential minimally invasive diagnostic marker for MM.
Initially, attempts were made to establish an assay using commercially available antibodies and to optimize it by including a biotin-streptavidin complex into the assay protocol. Subsequently, a novel ELISA based on polyclonal antibodies raised in rabbit immunized with human recombinant calretinin was developed. The assay performance in human serum and plasma (EDTA/heparin) and the influence of calcium concentrations on antibody recognition were studied. Stability of spiked-in calretinin in EDTA plasma under different storage conditions was also examined. In preliminary studies serum and plasma samples from 97 healthy volunteers, 35 asbestos-exposed workers, and 42 MM patients were analyzed.
The mean detection range of the new ELISA was 0.12 to 8.97 ng/ml calretinin. The assay demonstrated markedly lower background and significantly higher sensitivity compared to the initially contrived assay that used commercial antibodies. Recovery rate experiments confirmed dependence of calretinin antibody recognition on calcium concentration. Calcium adjustment is necessary for calretinin measurement in EDTA plasma. Spiked-in calretinin revealed high stability in EDTA plasma when stored at room temperature, 4 degrees C, or after repeated freeze/thaw cycles. Median calretinin values in healthy volunteers, asbestos workers, and MM patients were 0.20, 0.33, and 0.84 ng/ml, respectively (p < 0.0001 for healthy vs. MM, p = 0.0036 for healthy vs. asbestos-exposed, p < 0.0001 for asbestos-exposed vs. MM). Median values in patients with epithelioid and biphasic MM were similar. No influence of age, gender, smoking status, or type of medium (plasma/serum) on calretinin values was found.
The novel assay is highly sensitive and applicable to human serum and plasma. Calretinin appears to be a promising marker for the blood-based detection of MM and might complement other markers. However, further studies are required to prove its usefulness in the diagnosis of MM patients.
钙结合蛋白(Calretinin)是恶性间皮瘤(MM)诊断中一种被广泛认可的免疫组织化学标志物。然而,其在人血液中的诊断工具用途却鲜有研究。本研究旨在开发一种用于人血液中钙结合蛋白的酶联免疫吸附测定法(ELISA),并评估其作为 MM 潜在微创诊断标志物的有用性。
最初,尝试使用市售抗体建立测定法,并通过将生物素-链霉亲和素复合物纳入测定方案来对其进行优化。随后,开发了一种基于用重组人钙结合蛋白免疫的兔多克隆抗体的新型 ELISA。研究了该测定法在人血清和血浆(EDTA/肝素)中的性能,以及钙浓度对抗体识别的影响。还研究了不同储存条件下 EDTA 血浆中掺入钙结合蛋白的稳定性。在初步研究中,分析了 97 名健康志愿者、35 名接触石棉的工人和 42 名 MM 患者的血清和血浆样本。
新 ELISA 的平均检测范围为 0.12 至 8.97ng/ml 钙结合蛋白。与最初使用商业抗体设计的测定法相比,该测定法的背景明显更低,灵敏度显著更高。回收实验证实钙结合蛋白抗体识别依赖于钙浓度。在 EDTA 血浆中进行钙结合蛋白测量需要进行钙调整。当 EDTA 血浆在室温、4°C 或反复冻融循环下储存时,掺入的钙结合蛋白显示出很高的稳定性。健康志愿者、接触石棉的工人和 MM 患者的中位钙结合蛋白值分别为 0.20、0.33 和 0.84ng/ml(健康与 MM 相比,p<0.0001;健康与接触石棉相比,p=0.0036;接触石棉与 MM 相比,p<0.0001)。上皮样和双相 MM 患者的中位值相似。钙结合蛋白值不受年龄、性别、吸烟状况或介质类型(血浆/血清)的影响。
新型测定法具有高度敏感性,适用于人血清和血浆。钙结合蛋白似乎是一种有前途的用于血液中 MM 检测的标志物,可能与其他标志物互补。然而,还需要进一步的研究来证明其在 MM 患者诊断中的有用性。